Albany Molecular Research, Inc.  

(Public, NASDAQ:AMRI)   Watch this stock  
Find more results for Sanofi US Services Inc
-0.47 (-2.80%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.21 - 16.78
52 week 10.28 - 23.95
Open 16.67
Vol / Avg. 363,176.00/583,778.00
Mkt cap 532.47M
P/E 184.27
Div/yield     -
EPS 0.09
Shares 32.61M
Beta 1.73
Inst. own 99%
Feb 12, 2015
Q4 2014 Albany Molecular Research Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 12, 2015
Q4 2014 Albany Molecular Research Inc Earnings Call - 8:30AM EST - Add to calendar
Jan 13, 2015
Albany Molecular Research Inc at JPMorgan Healthcare Conference
Jan 9, 2015
Albany Molecular Research Inc Conference Call to Acquire Aptuit Drug Product Development and Aseptic Clinical Manufacturing Businesses
Nov 12, 2014
Albany Molecular Research Inc at Credit Suisse Healthcare Conference
Nov 5, 2014
Q3 2014 Albany Molecular Research Inc Earnings Release
Nov 5, 2014
Q3 2014 Albany Molecular Research Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -13.83% 5.14%
Operating margin -15.58% 8.18%
EBITD margin - 18.28%
Return on average assets -6.58% 3.58%
Return on average equity -13.91% 5.67%
Employees 1,282 -
CDP Score - -


ALBANY, NY 12203-5154
United States - Map
+1-518-4640279 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Albany Molecular Research, Inc. (AMRI) is a contract research and manufacturing company. The Company provides customers with fully integrated drug discovery, development and manufacturing services. The Company operates in two segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small Scale Manufacturing (DDS). Its LSM segment activities include pilot to commercial scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling and high potency and controlled substance manufacturing and its remaining activities, including drug lead discovery, optimization, drug development, and small scale commercial manufacturing represent its DDS business segment. In March 2014, the Company acquired Cedarburg Pharmaceuticals Inc. In July 2014, AMRI acquired Oso Biopharmaceuticals Manufacturing, former portfolio company of Altaris Capital Partners, LLC.

Officers and directors

William S. Marth President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael M. Nolan Chief Financial Officer, Senior Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
George Svokos Senior Vice President - Sales, General Manager - API
Age: 56
Bio & Compensation  - Reuters
Steven R. Hagen Ph.D. Senior Vice President - Manufacturing and Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Michael A. Luther Ph.D. Senior Vice President - Discovery Services
Age: 58
Bio & Compensation  - Reuters
Lori M. Henderson Esq. Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Thomas E. D' Ambra Ph.D. Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Una S. Ryan Ph.D., OBE Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Veronica G. H. Jordan Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Gabriel Leung Independent Director
Age: 52
Bio & Compensation  - Reuters